PathCision Medicine — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PathCision Medicine is a private, preclinical-stage biotech founded in 2021 and headquartered in Cambridge, Massachusetts. The company has developed a proprietary discovery platform that integrates computational pathology, machine learning, and deep biological understanding to identify novel therapeutic pathways from tissue data. This platform fuels an internal pipeline of targeted therapies aimed at complex diseases, with an initial focus on transforming cancer treatment. The company is led by a team with expertise in translational medicine, pathology, and AI, positioning it at the intersection of digital pathology and drug discovery.

Oncology

Technology Platform

Proprietary AI-driven discovery platform that combines computational pathology and machine learning to analyze tissue biology and identify novel therapeutic targets.

Funding History

1

SeedUndisclosedUndisclosedJun 15, 2023

Opportunities

The large and growing precision oncology market, coupled with increasing pharma reliance on AI for R&D efficiency, presents a significant opportunity.

Successfully validating its platform could position PathCision as a partner for large pharma or an attractive acquisition target, while its internal pipeline offers substantial upside.

Risk Factors

Key risks include the unproven validation of its AI platform in generating clinical-stage assets, intense competition in the AI-drug discovery space, and the inherent high failure rate and cost of drug development.

Securing ongoing funding is also a critical challenge.

Competitive Landscape

PathCision competes in the crowded AI-for-drug-discovery sector against companies like Recursion, Exscientia, and Insilico Medicine, as well as internal efforts at large pharma. Its differentiation lies in its specific focus on deep tissue pathology insights, led by a pathologist-founder, which may offer a unique angle on target discovery compared to genomics-centric or chemistry-first AI approaches.

More companies in Diagnostics & Precision Medicine →More companies in United States →